<DOC>
	<DOCNO>NCT00497146</DOCNO>
	<brief_summary>To evaluate effect paricalcitol capsule cardiac structure function 48 week patient Stage 3/4 chronic kidney disease ( CKD ) leave ventricular hypertrophy ( LVH ) .</brief_summary>
	<brief_title>The PRIMO Study : Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity Subjects With Chronic Kidney Disease Stage 3/4</brief_title>
	<detailed_description>Patients meet inclusion criterion meet exclusion criterion randomize 1:1 ratio treatment group receive paricalcitol capsule placebo . A stratified randomization scheme use ensure balance among treatment group respect country , gender , baseline renin angiotensin-aldosterone system ( RAAS ) inhibitor use ( yes/no ) . Participants complete 48-Week Treatment Period could continue ongoing Long-term Follow-up Period last 18 month , study visit 6 month , 12 month 18 month post Treatment Week 48 Visit . Participants receive study drug , undergone echocardiogram/MRI procedure Long-term Follow-up Period .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Hypertrophy , Left Ventricular</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Estimated glomerular filtration rate ( GFR ) 1560 mL/min/1.73 m^2 Serum intact parathyroid hormone ( iPTH ) value 50300 pg/mL Corrected serum calcium level 8.010.0 mg/dL ( 2.02.5 mmol/L ) Phosphorous level less equal 5.2 mg/dL ( 1.68 mmol/L ) Serum albumin great equal 3.0 g/dL ( 30 g/L ) Echocardiogram result : Females : Left ventricular ( LV ) ejection fraction great equal 50 % septal wall thickness 1117 mm ; , Males : LV ejection fraction great equal 50 % septal wall thickness 1218 mm If subject receive reninangiotensinaldosterone system ( RAAS ) inhibitor dose must stable great one month prior Screening Period . However , subject may switch different brand equivalent dos determine study physician month prior Screening Period . Subject must technically adequate baseline cardiac magnetic resonance imaging ( MRI ) . Subject previously active vitamin D therapy within four week prior Screening Period Pregnant lactate female Subject expect initiate renal replacement therapy within one year Subject take calcitonin , bisphosphonates , cinacalcet , glucocorticoid ( except topical inhaled glucocorticoid ) Subject clinically significant coronary artery disease ( CAD ) within 3 month prior Screening Period , define either hospitalization myocardial infarction ( MI ) unstable angina ; new onset angina positive functional study coronary angiogram reveal stenosis ; coronary revascularization procedure . Subject major cardiac valve abnormality link LVH and/or diastolic dysfunction , define either aortic valve area â‰¤ 1.5 cm^2 mean gradient &gt; 20 mmHg ; regurgitation lesion ; moderate mitral regurgitation , moderate aortic regurgitation . Subject asymmetric septal hypertrophy define septal wall thickness/posterior wall thickness ratio &gt; 1.5 base screen echocardiogram . Subject severe cerebrovascular accident ( CVA ) within last 3 month ( e.g. , hemorrhagic ) prior screen . Subject full remission malignancy le 1 year except completely excise nonmelanoma skin cancer ( e.g. , basal squamous carcinoma ) history bone metastasis . Subject comorbid condition ( e.g. , advanced malignancy , advance liver disease ) life expectancy le 1 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>paricalcitol</keyword>
	<keyword>Zemplar</keyword>
	<keyword>PRIMO</keyword>
	<keyword>Chronic Kidney Disease Stage 3B/4</keyword>
</DOC>